Brukinsa

Active Ingredient(s): Zanubrutinib
FDA Approved: * November 14, 2019
Pharm Company: * BEIGENE
Category: Cancer

Zanubrutinib, sold under the brand name Brukinsa, is a medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL).[3][7][8][9] Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor.[3] It is given by mouth.[3] It was approved for medical use in the United States in November 2019.[10]... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Brukinsa 80 mg Oral Capsule, Gelatin Coated

NDC: 72579-011

Labeler:

Beigene USA, Inc.